Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-02-27
2007-02-27
Siew, Jeffrey (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C530S387700, C530S389100, C435S007100
Reexamination Certificate
active
10368912
ABSTRACT:
The invention discloses two newly-discovered Flt3 phosphorylation sites, tyrosine 589 (Tyr589) and tyrosine 591 (Tyr591) in the intracellular domain, and provides antibodies, both polyclonal and monoclonal, that selectively bind to Flt3 when phosphorylated at these novel sites. Also provided are assays utilizing these reagents, including methods for determining the phosphorylation of Flt3 in a biological sample, selecting a patient suitable for Flt3 inhibitor therapy, profiling Flt3 activation in a test tissue, and identifying a compound that modulates phosphorylation of Flt3 in a test tissue, by using a detectable reagent, such as the disclosed antibodies, that binds to Flt3 when phosphorylated at Tyr589 or Tyr591. The sample or test tissue may be taken from a subject suspected of having cancer, such as acute myelogenous leukemia (AML).
REFERENCES:
patent: 5635388 (1997-06-01), Bennett et al.
patent: 5777084 (1998-07-01), Buhring
patent: 6156882 (2000-12-01), Buhring
PharMingen (Transduction Laboratories and PharMingen 1999 Cell Biology Sourcebook, 1999, pp. 242-245).
Glenney et al (Journal of Immunological Methods, 1988, 109:277-285).
Aaronson,Science 254: 1146-52 (1991).
Schlessinger et al., Neuron 9: 383-391 (1992).
Neāl et al.,Lancet 1: 366-68 (1985).
Sainsbury et al.,Lancet 1: 1398-1402 (1987).
Yokota et al.,Lancet 1: 765-67 (1986).
Fukushige et al.,Mol. Cell. Biol. 6: 955-58 (1986).
Rosnet et al.,Blood 82(4): 1110-1119 (1993).
Casteran et al.,Cell Mol. Biol. 40(3): 443-56 (1994).
Beslu et al.,J. Biol. Chem. 271: 20075-81 (1996).
Whitman et al.,Cancer Res. 61(19): 7233-39 (2001).
Kottardis et al.,Blood 98(6): 1752-59 (2001).
Timeus et al.,Lab Invest. 81(7): 1025-37 (2001).
Zwierzina et al.,Leukemia 13(4): 553-57 (1999).
Abu-Duhier et al.,Br. J. Haematol 113(4): 983-88 (2001).
Naoe et al.,Cancer Chemother. Pharmacol. 48: Suppl. 1: S27-30 (2001).
Weisberg et al.,Cancer Cell 1(5): 433-43 (2002).
Kelly et al.,Cancer Cell 1(5): 421-32 (2002).
Wybenga-Groot et al.,Cell 106(6): 745-57 (2001).
Comb Michael J.
Crosby Katherine
Wetzel Randall K.
Wu Jiong
Aeder Sean E
Cell Signaling Technology Inc.
Cell Signaling Technology, Inc.
Cullem, Esq. James G.
Siew Jeffrey
LandOfFree
Phospho-specific antibodies to Flt3 and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phospho-specific antibodies to Flt3 and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phospho-specific antibodies to Flt3 and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3809814